Breathing in a Warming World: Uncovering the Environmental Impact of Respiratory Care
In a world grappling with climate change, a hidden cost is taking its toll on our health systems. From the smoke-filled skies of wildfires to the daily use of inhalers, the very treatments for respiratory ailments are contributing to the very problem they aim to alleviate. But here's where it gets controversial: the health institutions treating these conditions are themselves part of the climate crisis.
Climate change is not just about rising temperatures; it's a complex web of interconnected issues. Extreme weather events, poor air quality, and prolonged pollen seasons are driving a surge in respiratory diseases. Over 90% of the global population breathes air that exceeds the World Health Organization's recommended levels of particulate matter, tiny air particles that can harm human health.
Experts highlight the significant link between respiratory illnesses and environmental factors. As wildfires rage and air pollution worsens, the air we breathe becomes increasingly hazardous, elevating the risks of respiratory exacerbations and disease progression. Therese Laperre, a respiratory specialist, warns that climate change is intensifying triggers for asthma and chronic respiratory diseases, altering the patterns of respiratory infections.
A study by the European Environment Agency reveals a startling connection: over a third of chronic respiratory disease deaths in Europe are linked to environmental factors like air pollution, extreme temperatures, wildfire smoke, and allergenic pollen. This vicious cycle is not just a health crisis; it's an environmental one too.
Worldwide, an estimated 400 to 500 million adults live with COPD, and over 250 million people battle asthma. The response from healthcare institutions comes at a climate cost. Health Care Without Harm, a non-profit organization, estimates that global health services generate a staggering five percent of worldwide greenhouse gas emissions, placing them among the world's top polluters if they were a country.
Without urgent action, emissions from healthcare are projected to reach an alarming six gigatons annually by 2050, equivalent to putting over a billion cars on the road. Hospitals, especially intensive care units, are major contributors to this impact due to their high energy consumption, equipment usage, and reliance on single-use materials.
Respiratory specialists emphasize the importance of early intervention by healthcare professionals. Early diagnosis and control of chronic diseases not only benefit patients but also reduce healthcare's climate footprint. Philippe Tieghem from Sante Respiratoire highlights the dual benefit of early detection: "It's good for patients, it's good for carbon, and it's economically advantageous."
Inhalers, a common treatment for long-term lung diseases, embody this dilemma. The most widely used inhalers, pressurized metered-dose inhalers, rely on gas propellants to deliver medicine directly to the lungs. These propellants, typically hydrofluorocarbons (HFCs), are potent greenhouse gases with a high global warming potential.
Recent estimates suggest that pressurized inhalers contribute roughly 4-5 million tonnes of CO₂-equivalent emissions annually in Europe and around 16-17 million tonnes globally, accounting for about 0.03% of total greenhouse gas emissions. The UK's National Health Service estimates that these inhalers constitute around three percent of its carbon footprint.
While these emissions are relatively small on a global scale, they are significant enough for health services and manufacturers to prioritize inhalers for decarbonization efforts. AstraZeneca's reformulated COPD inhaler, approved in the UK and the EU, is a step towards greener alternatives. This inhaler contains the same active medicines but uses a new propellant, HFO-1234ze(E), reducing its warming impact by approximately 99.9% compared to the old gas.
Pharmaceutical companies are taking notice and pledging to reduce their emissions. AstraZeneca aims to cut its emissions by 98% by 2026, starting with inhalers and addressing scope 3 emissions linked to suppliers and product use. Pablo Panella, senior vice-president for respiratory diseases, emphasizes the company's mission: "We focus on prevention, early detection, and treatment to keep patients stable in the community, freeing up hospital capacity, which is often more costly and critical, especially in acute situations."
Other major drugmakers, like Pfizer and Johnson & Johnson, have committed to reaching net-zero emissions by 2040 and 2045, respectively. Better control of chronic diseases translates to fewer emergency admissions and less need for resource-intensive care. The pharmaceutical industry refers to this as a "green patient" - a person whose disease is well-managed, avoiding repeated flare-ups and high-carbon interventions.
For the industry, technology is just one piece of the puzzle. The other is regulatory support. Panella highlights the need for regulations that facilitate innovation, particularly in reducing environmental footprints. "Regulations should be welcoming and not overly complex. Developing technology is one thing, but ensuring it reaches patients in a timely manner is crucial,"
As we navigate the complexities of climate-conscious regulation, the question is not whether it should support environmental initiatives but how to design it to foster innovation and investment in low-carbon solutions. The future of respiratory care lies in finding a balance between effective treatment and environmental sustainability.
